↓ Skip to main content

Cardiovascular Complications Associated With Novel Cancer Immunotherapies

Overview of attention for article published in Current Treatment Options in Cardiovascular Medicine, April 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#12 of 250)
  • High Attention Score compared to outputs of the same age (88th percentile)
  • High Attention Score compared to outputs of the same age and source (92nd percentile)

Citations

dimensions_citation
30 Dimensions

Readers on

mendeley
34 Mendeley
Title
Cardiovascular Complications Associated With Novel Cancer Immunotherapies
Published in
Current Treatment Options in Cardiovascular Medicine, April 2017
DOI 10.1007/s11936-017-0532-8
Pubmed ID
Authors

Varun Jain, Jaspreet Bahia, Mahsa Mohebtash, Ana Barac

Abstract

Immune therapies represent a quantum leap in the fight against cancer. Recently approved immune checkpoint inhibitors that target receptors involved in immune escape of cancer cells (including cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), programmed cell death protein-1 (PD-1), and programmed cell death protein ligand-1 (PD-L1) are increasingly being used for therapeutic benefit in a number of cancers. The robust anti-cancer activity of these agents has been accompanied by the recognition of new adverse effects, often due to the over activation of immune system, that may limit their therapeutic benefit and adversely impact outcomes. Combination treatments in particular, such as approaches using two targeted immunotherapy agents, have higher risk of adverse effects. Our review focuses on the approved checkpoint inhibitor therapies and their potential for cardiovascular toxicity. While very few cases of autoimmune cardiotoxicity and myocarditis have been reported in clinical trials, severe, life-threatening episodes of heart failure and hemodynamic compromise associated with the use of immune checkpoint inhibitors have recently been reported in the literature. Early recognition, diagnosis, and management of autoimmune myocarditis represent an important clinical challenge with no current guidelines available for prevention, identification, and treatment of this serious condition. This area of cardio-oncology is evolving rapidly as more drugs in this class are being discovered and pending approval. There is a need for future studies focused on prospective identification of biomarkers and clinical standards for treatment and long-term follow-up of cardiovascular toxicity to successfully continue the treatment of cancer while preventing the adverse outcomes with novel immune therapies.

Twitter Demographics

The data shown below were collected from the profiles of 9 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 34 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 3%
Unknown 33 97%

Demographic breakdown

Readers by professional status Count As %
Other 8 24%
Researcher 6 18%
Student > Doctoral Student 5 15%
Student > Master 4 12%
Unspecified 2 6%
Other 9 26%
Readers by discipline Count As %
Medicine and Dentistry 23 68%
Unspecified 5 15%
Biochemistry, Genetics and Molecular Biology 2 6%
Nursing and Health Professions 1 3%
Agricultural and Biological Sciences 1 3%
Other 2 6%

Attention Score in Context

This research output has an Altmetric Attention Score of 17. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 January 2018.
All research outputs
#795,323
of 12,400,657 outputs
Outputs from Current Treatment Options in Cardiovascular Medicine
#12
of 250 outputs
Outputs of similar age
#30,258
of 263,563 outputs
Outputs of similar age from Current Treatment Options in Cardiovascular Medicine
#1
of 13 outputs
Altmetric has tracked 12,400,657 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 250 research outputs from this source. They receive a mean Attention Score of 4.4. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 263,563 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.